Exploration of Immunology

Table 1. List of vaccines and their efficacy and reported side effects

COVID vaccines	Efficacy	Adverse effect	References
Moderna: mRNA-1273	94.4%	Pain, swelling and erythema at the injection site, headache, fatigue, chills, arthralgia, myalgia, nausea/vomiting, axillary swelling, fever, and an allergic reaction which includes anaphylaxis, myocarditis, pericarditis, and syncope	[66–71]
Pfizer: BNT162b1	91.7%	Injection site reaction (redness, pain, swelling, and pruritus), fatigue, headache, myalgias fever, chills, and joint pain	[73, 74]
Janssen (Johnson & Johnson): Ad26.COV2. S	93.1%	Pain, headache, fatigue, and anxiety-related events which included tachycardia, hyperventilation, light-headedness, and syncope	[84, 85]
Oxford/AstraZeneca: AZD1222	70.4%	Pain at the injection site, headache, fatigue, fever, transverse myelitis, and sclerosis	[86, 90]
Sinopharm: BBIBP-CorV	79%	Normal injection site pain, fatigue, headache, lethargy, and tenderness	[93]
Sinovac (CoronaVac)	83.5%	Pain at the injection site, redness, increased temperature, and systemic side effects are very less	[99]
Covaxin: BBV152	78%	Muscle pain, fever, pain at the injection site, headache, and fatigue	[101]

Return to article view

Declarations

Acknowledgments

We thank the Director, CSIR-CFTRI for providing facilities to carry out this work. The corresponding author would like to thank the Department of Biotechnology (DBT), Govt. of India for providing the Ramalingaswami Fellowship during the study.

Author contributions

RPV: conceptualization and supervision and final draft preparation. BRS: data curation, original draft preparation. Both of the authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135–49. [DOI] [PubMed]

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. [DOI] [PubMed] [PMC]

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4. [DOI] [PubMed] [PMC]

Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185–92. [DOI] [PubMed] [PMC]

Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9:45. [DOI] [PubMed] [PMC]

Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18:348–64. [DOI] [PubMed] [PMC]

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–7. [DOI] [PubMed] [PMC]

Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–21. [DOI] [PubMed] [PMC]

Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020;52:737–41. [DOI] [PubMed] [PMC]

10.

Brett TS, Rohani P. COVID-19 herd immunity strategies: walking an elusive and dangerous tightrope. medRxiv [Preprint]. 2020 [cited 2020 May 5]. Available from: https://pubmed.ncbi.nlm.nih.gov/32511597/

11.

Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6:104. [DOI] [PubMed] [PMC]

12.

Kara E, Tanir F, Demirhindi H, Mete B, Kibar F, Cetiner S, et al. Humoral immune response in inactivated SARS-CoV-2 vaccine: when should a booster dose be administered? medRxiv [Preprint]. 2021 [cited 2021 Jul 13]. Available from: https://www.medrxiv.org/content/10.1101/2021.07.08.21260194v1

13.

Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O’Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6–9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9:350–9. [DOI]

14.

Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependentaxis. Cell Metab. 2020;32:498–9. Erratumfor: Cell Metab. 2020;32:437–46.e5. [DOI] [PubMed] [PMC]

15.

Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21:1485–6. Erratum in: Lancet Infect Dis. 2022;22:e1. [DOI] [PubMed] [PMC]

16.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–23. [DOI] [PubMed] [PMC]

17.

Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al.; Virus Watch Collaborative. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385–7. [DOI] [PubMed] [PMC]

18.

Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27:1379–84. [DOI] [PubMed] [PMC]

19.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385:585–94. [DOI] [PubMed] [PMC]

20.

Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399:625–6. Erratum in: Lancet. 2022;399:628. [DOI] [PubMed] [PMC]

21.

Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA. 2022;327:1286–8. [DOI] [PubMed] [PMC]

22.

Hernandez RG, Hagen L, Walker K, O’Leary H, Lengacher C. The COVID-19 vaccine social media infodemic: healthcare providers’ missed dose in addressing misinformation and vaccine hesitancy. Hum Vaccin Immunother. 2021;17:2962–4. [DOI] [PubMed] [PMC]

23.

Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21:395–404. [DOI] [PubMed] [PMC]

24.

Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147:545–57.e9. [DOI] [PubMed] [PMC]

25.

Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383:1724–34. [DOI] [PubMed] [PMC]

26.

Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2020;15:e0244126. [DOI] [PubMed] [PMC]

27.

Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. [DOI] [PubMed] [PMC]

28.

Röltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025–40.e14. [DOI] [PubMed] [PMC]

29.

Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12:1162. [DOI] [PubMed] [PMC]

30.

Yang X, Dai T, Zhou X, Qian H, Guo R, Lei L, et al. Naturally activated adaptive immunity in COVID-19 patients. J Cell Mol Med. 2020;24:12457–63. [DOI] [PubMed] [PMC]

31.

Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 2009;83:3039–48. [DOI] [PubMed] [PMC]

32.

Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2004;101:15748–53. [DOI] [PubMed] [PMC]

33.

Jørgensen K, Praestegaard J, Holen M. The conditions of possibilities for recovery: a critical discourse analysis in a Danish psychiatric context. J Clin Nurs. 2020;29:3012–24. [DOI] [PubMed]

34.

Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008;133:13–9. [DOI] [PubMed] [PMC]

35.

Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW. Visualizing priming of virus-specific CD8⁺ T cells by infected dendritic cells in vivo. Nat Immunol. 2002;3:265–71. [DOI] [PubMed]

36.

Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003;349:508–9. [DOI] [PubMed]

37.

Casanova JL, Su HC; COVID human genetic effort. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell. 2020;181:1194–9. [DOI] [PubMed] [PMC]

38.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–5. [DOI] [PubMed] [PMC]

39.

Qin CC, Liu YN, Hu Y, Yang Y, Chen Z. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury. World J Gastroenterol. 2017;23:3043–52. [DOI] [PubMed] [PMC]

40.

Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7:998–1002. [DOI] [PubMed] [PMC]

41.

Huang H, Wang S, Jiang T, Fan R, Zhang Z, Mu J, et al. High levels of circulating GM^–CSF⁺CD4⁺ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study. Cell Mol Immunol. 2019;16:602–10. [DOI] [PubMed] [PMC]

42.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2. Erratum in: Lancet Respir Med. 2020;8:e26. [DOI] [PubMed] [PMC]

43.

Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–4. [DOI] [PubMed] [PMC]

44.

Young RE, Thompson RD, Larbi KY, La M, Roberts CE, Shapiro SD, et al. Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo. J Immunol. 2004;172:4493–502. [DOI] [PubMed]

45.

Liu S, Su X, Pan P, Zhang L, Hu Y, Tan H, et al. Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury. Sci Rep. 2016;6:37252. [DOI] [PubMed] [PMC]

46.

Koutsogiannaki S, Shimaoka M, Yuki K. The use of volatile anesthetics as sedatives for acute respiratory distress syndrome. Transl Perioper Pain Med. 2019;6:27–38. [DOI] [PubMed] [PMC]

47.

Small BA, Dressel SA, Lawrence CW, Drake DR 3rd, Stoler MH, Enelow RI, et al. CD8⁺ T cell-mediated injury in vivo progresses in the absence of effector T cells. J Exp Med. 2001;194:1835–46. [DOI] [PubMed] [PMC]

48.

Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–22. [DOI] [PubMed] [PMC]

49.

Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, et al. Durable humoral and cellular immune responses following Ad26.COV2.S vaccination for COVID-19. medRxiv [Preprint]. 2021 [cited 2021 Jul 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/34268527/

50.

Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6:eabi6950. [DOI] [PubMed] [PMC]

51.

Sokal A, Barba-Spaeth G, Fernandez I, Broketa M, Azzaoui I, de La Selle A, et al. Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals. bioRxiv [Preprint]. 2021 [cited 2021 Jun 17]. Available from: https://europepmc.org/article/PPR/PPR358603

52.

Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020;58:e02107–20. [DOI] [PubMed] [PMC]

53.

Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369:806–11. [DOI] [PubMed] [PMC]

54.

Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945–6. [DOI] [PubMed]

55.

Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 vaccine development: current status. Mayo Clin Proc. 2020;95:2172–88. [DOI] [PubMed] [PMC]

56.

Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. [DOI] [PubMed] [PMC]

57.

Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583–9. [DOI] [PubMed] [PMC]

58.

Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–71. [DOI] [PubMed] [PMC]

59.

Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–55. [DOI] [PubMed] [PMC]

60.

Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al.; mRNA-1273 Study Group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–2. [DOI] [PubMed] [PMC]

61.

Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al.; mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39:2791–9. [DOI] [PubMed] [PMC]

62.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. [DOI] [PubMed] [PMC]

63.

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al.; mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–38. [DOI]

64.

Dolgin E. Quarter-dose of Moderna COVID vaccine still rouses a big immune response. Nature. 2021;[Epub ahead of print]. [DOI] [PubMed]

65.

Tanne JH. Covid-19: moderna plans booster doses to counter variants. BMJ. 2021;372:n232. [DOI] [PubMed]

66.

Malayala SV, Mohan G, Vasireddy D, Atluri P. Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine. Cureus. 2021;13:e14099. [DOI] [PubMed] [PMC]

67.

Wei N, Fishman M, Wattenberg D, Gordon M, Lebwohl M. “COVID arm”: a reaction to the Moderna vaccine. JAAD Case Rep. 2021;10:92–5. [DOI] [PubMed] [PMC]

68.

Mahase E. Covid-19: moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ. 2020;371:m4471. [DOI]

69.

Channa L, Torre K, Rothe M. Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination. JAAD Case Rep. 2021;15:60–1. [DOI] [PubMed] [PMC]

70.

Williams CB, Choi JI, Hosseini F, Roberts J, Ramanathan K, Ong K. Acute myocarditis following mRNA-1273 SARS-CoV-2 vaccination. CJC Open. 2021;3:1410–2. [DOI] [PubMed] [PMC]

71.

Perez B, Sims HS, Mularczyk C. Vocal cord paresis: a case report on a novel complication of the mode RNA COVID-19 vaccine. Otolaryngol Head Neck Surg. 2021;165:P242.

72.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. [DOI] [PubMed] [PMC]

73.

Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–50. [DOI] [PubMed] [PMC]

74.

Baron EL, Bloom DA, Mitty J, Bond S, Bogorodskaya M, Hall KK, editor. What’s new in infectious diseases [Internet]. UpToDate, Inc.; c2022 [cited 2022 Jun 30]. Available from: https://www.uptodate.com/contents/whats-new-in-infectious-diseases

75.

Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–50. [DOI] [PubMed] [PMC]

76.

Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385:e84. [DOI] [PubMed] [PMC]

77.

Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393–400. [DOI] [PubMed] [PMC]

78.

Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325:2201–2. [DOI] [PubMed]

79.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al.; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. [DOI] [PubMed] [PMC]

80.

Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021;325:1535–44. [DOI] [PubMed] [PMC]

81.

Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022;98:389–94. [DOI] [PubMed]

82.

Collier AY, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N Engl J Med. 2021;385:2010–2. [DOI] [PubMed] [PMC]

83.

Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:680–4. [DOI] [PubMed] [PMC]

84.

Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination - five U.S. mass vaccination sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:685–8. [DOI] [PubMed] [PMC]

85.

Takuva S, Takalani A, Garrett N, Goga A, Peter J, Louw V, et al. Thromboembolic events in the South African Ad26.COV2.S vaccine study. N Engl J Med. 2021;385:570–1. [DOI] [PubMed] [PMC]

86.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. Erratum in: Lancet. 2020;396:466. Erratum in: Lancet. 2020;396:1884. [DOI] [PubMed] [PMC]

87.

Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al.; Oxford COVID Vaccine Trial group. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398:981–90. [DOI]

88.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–93. Erratum in: Lancet. 2021;396:1978. Erratum in: Lancet. 2021;397:1350. [DOI]

89.

Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine. 2022;40:524–30. [DOI] [PubMed] [PMC]

90.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91. Erratum in: Lancet. 2021;397:880.

91.

BBIBP-CorV, sinopharm COVID-19 vaccine [Internet]. [cited 2021 Apr 12]. Available from: https://newdrugapprovals.org/2021/03/23/bbibp-corv-sinopharm-covid-19-vaccine/

92.

Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Jayathilaka D, et al. Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv [Preprint]. 2021 [cited 2021 Oct 18]. Available from: https://www.medrxiv.org/content/10.1101/2021.07.15.21260621v1

93.

Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219–26. [DOI] [PubMed] [PMC]

94.

Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al.; CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–22. Erratum in: Lancet. 2022;399:436. [DOI] [PubMed]

95.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92. [DOI]

96.

Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:1645–53. [DOI]

97.

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:803–12. [DOI]

98.

Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22:483–95. [DOI] [PubMed] [PMC]

99.

Uzer F, Cilli A. Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac^®): a case report. Med Gas Res. 2022;12:67–8. [DOI] [PubMed] [PMC]

100.

Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, et al. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience. 2021;24:102298. [DOI] [PubMed] [PMC]

101.

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al.; COVAXIN Study Group. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398:2173–84. [DOI] [PubMed] [PMC]